Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Wu, Joseph C  [Clear All Filters]
2019
Kernik, D.C., Morotti, S., Wu, H., Garg, P., Duff, H.J., Kurokawa, J., Jalife, J., Wu, J.C., Grandi, E., and Clancy, C.E. (2019). A computational model of induced pluripotent stem-cell derived cardiomyocytes incorporating experimental variability from multiple data sources.J Physiol.
Williams, I.M., and Wu, J.C. (2019). Generation of Endothelial Cells From Human Pluripotent Stem Cells.Arterioscler Thromb Vasc Biol39, 1317-1329.
Wang, L., Pegram, M.D., and Wu, J.C. (2019). Induced Pluripotent Stem Cells as a Novel Cancer Vaccine.Expert Opin Biol Ther.
Wu, H., Yang, H., Rhee, J.-W., Zhang, J.Z., Lam, C.Keung, Sallam, K., C Y Chang, A., Ma, N., Lee, J., Zhang, H., et al. (2019). Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.Eur Heart J.
Wu, J.C., Garg, P., Yoshida, Y., Yamanaka, S., Gepstein, L., Hulot, J.-S., Knollmann, B.C., and Schwartz, P.J. (2019). Towards Precision Medicine With Human iPSCs for Cardiac Channelopathies.Circ Res125, 653-658.
Abi-Gerges, N., McMahon, C., Vargas, H., Sager, P., Chui, R., Stevens, D., Davila, J., Schaub, J.R., Wu, J.C., Del Rio, C., et al. (2019). The West coast regional safety pharmacology society meeting update: Filling translational gaps in safety assessment.J Pharmacol Toxicol Methods106582.
Pang, L., Sager, P., Yang, X., Shi, H., Sannajust, F., Brock, M., Wu, J.C., Abi-Gerges, N., Lyn-Cook, B., Berridge, B.R., et al. (2019). Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms.Circ Res125, 855-867.
2018
Lam, C.Keung, and Wu, J.C. (2018). Disease modelling and drug discovery for hypertrophic cardiomyopathy using pluripotent stem cells: how far have we come?.Eur Heart J.
Garg, P., Oikonomopoulos, A., Chen, H., Li, Y., Lam, C.Keung, Sallam, K., Perez, M., Lux, R.L., Sanguinetti, M.C., and Wu, J.C. (2018). Genome Editing of Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant.J Am Coll Cardiol72, 62-75.
Wnorowski, A., Yang, H., and Wu, J.C. (2018). Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models.Adv Drug Deliv Rev.
Lau, E., Paik, D.T., and Wu, J.C. (2018). Systems-Wide Approaches in Induced Pluripotent Stem Cell Models.Annu Rev Pathol.
2016
Nguyen, P.K., Rhee, J.-W., and Wu, J.C. (2016). Adult Stem Cell Therapy and Heart Failure, 2000 to 2016: A Systematic Review.Jama Cardiol.
Burridge, P.W., Li, Y.Fuga, Matsa, E., Wu, H., Ong, S.-G., Sharma, A., Holmström, A., Chang, A.C., Coronado, M.J., Ebert, A.D., et al. (2016). Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.Nat Med.
Chanana, A.M., Rhee, J.-W., and Wu, J.C. (2016). Human-induced pluripotent stem cell approaches to model inborn and acquired metabolic heart diseases.Curr Opin Cardiol.
Sa, S., Gu, M., Chappell, J., Shao, N.-Y., Ameen, M., Elliott, K.A.T., Li, D., Grubert, F., Li, C.G., Taylor, S., et al. (2016). iPSC Model of Pulmonary Arterial Hypertension Reveals Novel Gene Expression and Patient Specificity.Am J Respir Crit Care Med.
Nguyen, P.K., Neofytou, E., Rhee, J.-W., and Wu, J.C. (2016). Potential Strategies to Address the Major Clinical Barriers Facing Stem Cell Regenerative Therapy for Cardiovascular Disease: A Review.Jama Cardiol.
Paik, K.J., Maan, Z.N., Zielins, E.R., Duscher, D., Whittam, A.J., Morrison, S.D., Brett, E.A., Ransom, R.C., Hu, M.S., Wu, J.C., et al. (2016). Short Hairpin RNA Silencing of PHD-2 Improves Neovascularization and Functional Outcomes in Diabetic Wounds and Ischemic Limbs.Plos One11, e0150927.
2015
He, N., Xu, Y., Du, W., Qi, X., Liang, L., Wang, Y., Feng, G., Fan, Y., Han, Z., Kong, D., et al. (2015). Extracellular Matrix can Recover the Downregulation of Adhesion Molecules after Cell Detachment and Enhance Endothelial Cell Engraftment.Sci Rep5, 10902.
Riegler, J., Tiburcy, M., Ebert, A., Tzatzalos, E., Raaz, U., Abilez, O.J., Shen, Q., Kooreman, N.G., Neofytou, E., Chen, V., et al. (2015). Human Engineered Heart Muscles Engraft and Survive Long-Term in a Rodent Myocardial Infarction Model.Circ Res.
Neofytou, E., O'Brien, C.Galen, Couture, L.A., and Wu, J.C. (2015). Hurdles to clinical translation of human induced pluripotent stem cells.J Clin Invest125, 2551-2557.
Haddad, F., Sever, M., Poglajen, G., Lezaic, L., Yang, P., Maecker, H., Davis, M., Kuznetsova, T., Wu, J.C., and Vrtovec, B. (2015). Immune Network and Response to Intramyocardial CD34+ Stem Cell Therapy in Patients with Dilated Cardiomyopathy.J Card Fail.
Wilson, K.D., and Wu, J.C. (2015). Induced Pluripotent Stem Cells.Jama313, 1613-1614.
2014
Burridge, P.W., Matsa, E., Shukla, P., Lin, Z.C., Churko, J.M., Ebert, A.D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N.M., et al. (2014). Chemically defined generation of human cardiomyocytes.Nat Methods.
Poglajen, G., Sever, M., Cukjati, M., Cernelc, P., Knezevic, I., Zemljic, G., Haddad, F., Wu, J.C., and Vrtovec, B. (2014). Effects of Transendocardial CD34+ Cell Transplantation in Patients With Ischemic Cardiomyopathy.Circ Cardiovasc Interv.
Bhattacharya, S., Burridge, P.W., Kropp, E.M., Chuppa, S.L., Kwok, W.-M., Wu, J.C., Boheler, K.R., and Gundry, R.L. (2014). High Efficiency Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes and Characterization by Flow Cytometry.J Vis Exp.

Pages